Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

430 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-25

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

NCT01828762

Primary Hepatocellular Carcinoma

COMPLETED NA

Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma

NCT02109146

Hepatocellular Carcinoma Transcatheter Arterial Chemoembolization

COMPLETED PHASE3

Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma

NCT02584556

Hepatocellular Carcinoma

WITHDRAWN PHASE2/PHASE3

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

NCT04102098

Carcinoma, Hepatocellular

ACTIVE_NOT_RECRUITING PHASE3

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

NCT04213118

Hepatocellular Carcinoma TACE Anlotinib

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HCC, accounting for 80% of all liver cancers, is the third most common cause of cancer-related death worldwide. Radical resection is considered as a curative strategy for patients with primary HCC. However, over 50% of patients experience recurrence after resection, resulting in a very low 5-year survival rate. EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood. This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection. Patients will be randomized in a 1:1 ratio to receive either 20 doses of EAL (1×10\^9\~2×10\^10 per dose) infusion in combination of a single TACE or a single TACE only. Primary endpoint is the independent review committee-determined recurrence-free survival (from randomization to first recurrence or death from any cause). Secondary endpoints include overall survival, cancer-specific survival, adverse events and others.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma (HCC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EAL Treatment Group

The patients with primary HCC will receive 12\~20 doses of EAL infusion (1×10\^9\~2×10\^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.

Group Type EXPERIMENTAL

Expanded Activated Lymphocytes (EAL)

Intervention Type BIOLOGICAL

12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.

transarterial chemoembolization (TACE)

Intervention Type PROCEDURE

After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.

Control Group

The patients with primary HCC will receive a single TACE after radical resection.

Group Type ACTIVE_COMPARATOR

transarterial chemoembolization (TACE)

Intervention Type PROCEDURE

After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Expanded Activated Lymphocytes (EAL)

12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.

Intervention Type BIOLOGICAL

transarterial chemoembolization (TACE)

After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with Stage Ia\~IIIa primary HCC with high recurrence risk (defined as single tumor ≥5cm in diameter, or single tumor \<5cm in diameter with MVI, PVTT, hepatic vein invasion, satellite lesions or AFP ≥400ng/mL, or multiple tumors).
2. Patients who have undergone a radical resection.
3. ECOG PS Score 0\~2.
4. Child-Pugh Score ≤ 7.
5. Patients with adequate hematologic and end-organ function.
6. HBV-HCC and HCV-HCC patients with active viral infection may receive antiviral treatment simultaneously.
7. Patients who have a life expectancy of at least 6 months.

Exclusion Criteria

1. Patients with a history of immune deficiency or autoimmune diseases (such as rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.).
2. Patients with a history of other malignant tumors in the past 5 years.
3. Patients who received chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, and hormone therapy within 1 month prior to screening.
4. Patients who have received microwave ablation, cryotherapy, high-power ultrasound focused ablation and other local ablation methods for liver tumors.
5. Patients with postoperative organ dysfunction or heart and lung diseases.
6. Patients allergic to albumin or with serious allergy history or mental disease.
7. Pregnant or lactating women.
8. Anticipated other clinical trials within 4 weeks before this trial.
9. Patients with HIV or Treponema pallidum infection, septicemia and other uncontrolled infection.
10. Patients after organ or bone marrow transplant.
11. Patients with drug or alcohol abuse/addiction.
12. Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No